US2021290654A1PendingUtilityA1

Altering microbial populations & modifying microbiota

Assignee: SNIPR TECH LTDPriority: May 6, 2015Filed: May 26, 2021Published: Sep 23, 2021
Est. expiryMay 6, 2035(~8.8 yrs left)· nominal 20-yr term from priority
Inventors:Jasper Clube
C12N 2795/10132C12N 15/902C12N 9/22A61K 2035/11A61K 35/74A61K 31/7105A01N 63/60A01N 63/50A01N 63/20A01N 63/00C12N 9/16C12N 2310/20C12N 15/113A61P 31/04A61K 48/005A61K 38/465C12N 15/746C12N 1/20A61K 31/711C12N 15/102C12N 15/70A61K 2300/00C12N 2320/31C12N 7/00A61K 45/06Y02A50/30C12N 2795/00032C12N 15/74
81
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An engineered nucleic acid vector comprising a host modifying (HM) CRISPR array the array comprising a spacer sequence (HM-spacer) and repeats encoding a HM-crRNA, the HM-crRNA comprising a sequence that is capable of hybridizing to a host cell target sequence to guide a Cas to the target in the host cell to modify the target sequence,
 wherein the host cell is a bacterial or archaeal cell,   and wherein vector comprises a HM-DNA, and the HM-DNA in the vector is flanked by site-specific recombination sites which can be cut by the action of a site specific recombinase.   
     
     
         2 . The vector of  claim 1 , wherein the HM-crRNA is operable with a Type I Cas. 
     
     
         3 . The vector of  claim 1 , wherein the HM-crRNA is operable with a Type II Cas. 
     
     
         4 . The vector of  claim 1 , wherein the HM-crRNA is operable with a Type III Cas. 
     
     
         5 . The vector of  claim 1 , wherein the Cas is a dead Cas, and the vector comprises a nucleotide sequence encoding the dead Cas. 
     
     
         6 . The vector of  claim 1 , wherein the vector does not comprise a Cas endonuclease-encoding sequence 
     
     
         7 . The vector of  claim 1 , wherein the vector is a phagemid. 
     
     
         8 . The vector of  claim 1 , wherein the vector is a plasmid. 
     
     
         9 . The vector of  claim 1 , wherein the vector comprises a nucleotide sequence encoding the site specific recombinase. 
     
     
         10 . A method of modifying a target nucleotide sequence of a host cell, comprising transforming the host cell with the vector of  claim 1 , wherein the site specific recombinase is encoded by the vector or by the host cell, wherein the modifying comprises inserting the HM-DNA at the target nucleotide sequence.

Join the waitlist — get patent alerts

Track US2021290654A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.